Skip to content
Tuesday, October 27, 2026 · Today’s edition, 6:30 a.m. ETTue, Oct 27 · 6:30 a.m. editionSign inMy Desk 0EditionsSign in

IBBvsSPMD

iShares Biotechnology ETF against SPDR Portfolio S&P 400 Mid Cap ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
IBB 133SPMD 110Oct 25Oct 26GROWTH OF $100
Head to head
IBBSPMD
Expense ratio0.45%0.030%
Assets$10.7B$18.4B
Net flow, 1 month+$150M+$319M
Net flow, 1 year+$1.7B+$2.4B
Return, YTD+23.7%+10.3%
Return, 1 year——
Avg daily volume1.6M2.2M
Holdings221401
ListedFeb 5, 2001Nov 8, 2005
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

ETF Dailyfrom Private Wealth Daily

ETF launches, fund research, and market coverage in your inbox every morning. Free.

Free. Every morning. Unsubscribe from any edition in one click.